Joseph K. Belanoff, MD, Chief Executive Officer, President and Director
Dr. Belanoff is a co-founder of Corcept Therapeutics and has served as a member of our Board and as our Chief Executive Officer since 1999. In 2013 he was also appointed President. Dr. Belanoff is currently a clinical faculty member and has held various positions in the Department of Psychiatry and Behavioral Sciences at Stanford University since 1992. From 1997 to 2001, he served as the Director of Psychopharmacology at the outpatient division of the Palo Alto Veterans Affairs Hospital. Dr. Belanoff received his B.A. from Amherst College and his M.D. from Columbia University's College of Physicians & Surgeons.
Thaddeus S. Block, MD, Vice President, Clinical Development
Dr. Block became Corcept’s Vice President, Clinical Development in 2015. He joined Corcept as Assistant Medical Director in 2004. Dr. Block has served as a clinical faculty member in the Department of Psychiatry and Behavioral Sciences at Stanford University since 2005, where he is involved in both resident education and the treatment of patients in the psychopharmacology clinic. Dr. Block graduated with honors from the University of California, Santa Cruz with a degree in biochemistry and molecular biology. He received his M.D. from the University of California, Los Angeles School of Medicine, where he was elected an alpha omega alpha member. He completed his internship and resident training at Stanford Hospital, finishing in the role of Chief Resident.
Robert S. Fishman, MD, Chief Medical Officer
Dr. Fishman joined Corcept as Chief Medical Officer in September 2015. He brings to the company more than 19 years of product development experience, most recently at InterMune, Inc., where from 2012 to 2015 he was Senior Vice President of Clinical Development and led the final pivotal trial of pirfenidone (Esbriet ®) for the treatment of idiopathic pulmonary fibrosis. From 2007 to 2012, he served as Vice President of Clinical Development at Alexza Pharmaceuticals, where he led the clinical development of inhaled loxapine (Adasuve®) for the treatment of agitation in patients with schizophrenia or bipolar disorder. Before that, Dr. Fishman held positions of increasing responsibility at Heartport, Aerogen, and Anthera Pharmaceuticals. He trained in internal medicine at Deaconess Hospital, Boston, completed a fellowship in pulmonary and critical care medicine at Massachusetts General Hospital, and began his career as a member of the Stanford pulmonary medicine faculty. He earned a B.A. from Harvard University and an M.D. from Stanford University School of Medicine.
Carolyn Hobbs, Vice President, Corporate Affairs
Ms. Hobbs joined Corcept as Vice President Corporate Affairs in April 2016. Carolyn brings over 20 years of pharmaceutical experience in multiple therapeutic areas to Corcept. Carolyn began her career in pharmaceutical sales at Parke-Davis in Toronto, Ontario. After five years of experience in consumer marketing at Adams Brands and Novartis Consumer Health and earning her MBA, Carolyn joined Sanofi in 2004 to work on the Plavix brand team. Subsequent to her roles on the Plavix team, she held positions of increasing responsibility in Marketing Operations, New Product Planning, and Launch Brands at Sanofi and Genzyme. In 2014, Carolyn was appointed Associate Vice President, New Product Excellence. In this role, she developed and implemented a launch platform that enhanced the company’s launch readiness, capabilities and success. Prior to joining Corcept, Carolyn was Associate Vice President, Chief of Staff for the North American President of Sanofi. Carolyn holds a B.A. from Princeton University and a MBA from the University of Western Ontario.
Hazel Hunt, PhD, Vice President, Research
Dr. Hunt joined Corcept in 2011, bringing with her more than 23 years of experience in the pharmaceutical and biotechnology industries. From 2002 to 2011 she was Director of Chemistry and Operations at Argenta, where she worked closely with Corcept and played an integral role in the discovery of Corcept’s portfolio of next-generation selective GR II antagonists. From 1994 to 2002 she worked for Celltech, initially as a Group Leader in Medicinal Chemistry and ultimately as Section Leader, Project Chemistry. From 1992 to 1994 she served as a Research Fellow at The Centre for Drug Design and Development. Before that Dr. Hunt worked at Glaxo Group Research as a Senior Chemist in Medicinal Chemistry. Dr. Hunt received a first class honors degree in chemistry from the Australian National University and a PhD in synthetic organic chemistry from the University of Southampton, UK. She also carried out post-doctoral work at Oxford University and the University of California at Irvine.
J.D. Lyon, Vice President, Corporate Controller
Mr. Lyon became Corcept’s Vice President, Corporate Controller in 2016. Prior to that, he was the company’s Director of Finance & Accounting. Before joining Corcept, Mr. Lyon served as the Director of Business Development and Operations for the Intermountain West Region of Connor Group, managing initial public offerings, mergers and acquisitions, IPO filings, and complex revenue recognition issues for companies in the pharmaceutical, biotech, and technology industries. Most recently he was the Worldwide Corporate Controller and General Manager – Americas for Zinfi Technologies, heading global finance and strategy. Mr. Lyon is a Certified Public Accountant. He began his career as an auditor with Ernst & Young, after graduating with B.A. and Master of Accountancy degrees from the University of Utah.
Sean Maduck, Senior Vice President, Commercial
Mr. Maduck was named Corcept’s Senior Vice President, Commercial in 2016. Prior to that, he was the company’s Vice President, Sales & Marketing. Mr. Maduck joined Corcept in 2012, bringing to the company 12 years of pharmaceutical, biotechnology and management experience. From 2002 to 2012, he held positions in the Finance, Portfolio Planning, and Commercial functions at Genentech. Prior to Genentech, he was an investment banking analyst at W.R Hambrecht + Company. He currently serves on the Board of Directors of the Cancer Support Community – San Francisco Bay Area. Mr. Maduck earned an A.B. from Dartmouth College, a B.E. in Biomedical Engineering from the Thayer School of Engineering at Dartmouth College, and a Masters in Management from the Stanford Graduate School of Business.
Susan Rinne, Vice President, Corporate Regulatory Affairs
Ms. Rinne joined Corcept as Vice President, Corporate Regulatory Affairs in March 2012. She has more than 25 years of United States and European regulatory affairs experience. Prior to Corcept, she served as Vice President of Regulatory Affairs at NeurogesX, Inc. from 2007 to 2012. From 1995 to 2007, she served in the roles of Director and Vice President of Regulatory Affairs at ALZA Corporation, a J&J company, with responsibilities for regulatory strategy and operations in support of new product development, global product registration, and marketed products. She began her career in Corporate Regulatory Affairs at Syntex Corporation. Ms. Rinne holds a B.S. in Biological Sciences and an M.S. in Pharmacology and Toxicology from the University of California, Davis.
Charles Robb, Chief Financial Officer
Mr. Robb joined us as Chief Financial Officer in September 2011. Mr. Robb has more than 25 years of experience in executive management, operations and finance. From April 2005 through August 2011 Mr. Robb served as the Senior Vice President of Operations, Administration and Finance of Fitness Anywhere, Inc., a fitness equipment and training company with operations in the United States, Europe and Asia. From 2003 to 2005, Mr. Robb was engaged in the private practice of law. From 2000 to 2002 he was Senior Vice President of Citadon, Inc. He also held positions in business development for Nomura Asset Capital Corporation from 1998 to 1999 and in sales and marketing for Legal Research Network, Inc. from 1996 to 1998. From 1992 to 1996 Mr. Robb practiced law at Howard, Rice, Nemerovski, Canady, Falk & Rabkin. Mr. Robb earned a B.A. in English and Political Philosophy from Yale and a J.D. from Harvard Law School, where he was a member of the Harvard Law Review.